Issue 6, March 2007 Dear Shareholders Welcome to the latest edition of Apollo Life, our regular newsletter to keep shareholders informed about our latest developments. If you would like any further information, please contact us. If you would like any further information, please contact us. Regards John Priest - CEO

HOT TOPIC:

Insulin in a tablet Using its own technology, Oradel?, Apollo is developing a tablet form of insulin. Preclinical studies show it is now possible to have a long-acting tablet instead of needles. We show why we are confident the human trials will be successful. In experiments, Oradel? insulin brings blood glucose levels into the normal range and holds them there for sustained periods of time, up to 24 hours.

IN BRIEF:

Thumbs up from Scientific Advisory Panel: Apollo?s proteins team was given the thumbs up from members of Apollo?s Scientific Advisory Panel at a meeting in Sydney this month for their work on the company?s innovative human cell expressed proteins. Meet Scientific Advisory Panel Members who attended the March meeting on proteins. Apollo on the ground in the US: Apollo has set up a presence for its proteins business, appointing Michael Hagen as Vice President of Sales and Marketing USA. He will be based in San Clemente, California.

Click here to subscribe

www.apollolifescience.com

 
Apollo Life Sciences Limited  ASX: AOP
Level 1, 147 Queen Street Beaconsfield NSW 2015 Australia
 
If you would prefer not to receive future email communications from Apollo Life Sciences, please
click here or reply to this message with the word REMOVE in the subject field.
You will receive one additional email confirming your removal.